Recent advances of vaccine adjuvants for infectious diseases - sprookjes - yvandenbroek - TriplyDB

Recent advances of vaccine adjuvants for infectious diseases

Recent advances of vaccine adjuvants for infectious diseases

http://www.wikidata.org/entity/Q28083679

about

Adjuvants: Classification, Modus Operandi, and Licensing Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro.HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Classification of Laser Vaccine Adjuvants QS-21: A Potent Vaccine Adjuvant.Novel platform technology for modular mucosal vaccine that protects against streptococcus.Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.Influenza infection in human host: challenges in making a better influenza vaccine.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.Anti-Infectious Human Vaccination in Historical Perspective.Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine.A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.Development of the CpG Adjuvant 1018: A Case Study.Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response.A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.The influence of adjuvant on UreB protection against Helicobacter pylori through the diversity of CD4+ T-cell epitope repertoire.Live-attenuated vaccination increases the diversity of pathogen-specific T cell repertoire triggered in chronic infection responses.Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells.malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.Perspectives in allergen immunotherapy: 2017 and beyond.A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation.Vaccine adjuvants: smart components to boost the immune system.Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.Host- and pathogen-derived adjuvant coatings on protein nanoparticle vaccines."Gnothi Seauton": Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy.Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.Nanoparticles in the clinic.RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants Against Emerging and Re-Emerging Viral Infections.Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development Immunogenicity and Protective Activity of a Chimeric Protein Based on the Domain III of the Tick-Borne Encephalitis Virus E Protein and the OmpF Porin of Incorporated into the TI-Complex Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis Synthesis of a hemin-containing copolymer as a novel immunostimulator that induces IFN-gamma production Prospects on the Use of sp. to Develop Oral Vaccines Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity

P2860

Q26747586-284D2657-16D2-4342-A8DB-C4303569FCB1 Q30382453-22D1496D-66DA-4EF0-8CB2-B7B8D83DEE82 Q30399700-BE434197-9341-4416-A246-FEBCAFCB97F1 Q33710401-BB850E12-8036-4A69-B850-628F2F564B12 Q35883997-A956296B-D89B-4F12-B508-8D02B67E35D3 Q35996738-5BE3ED92-D23E-45DD-92A2-69D44AEAAFB2 Q36920746-2AD59E25-837C-4F4B-B0C5-B22CB9DA9017 Q37504796-D63B3723-F478-4816-BCFF-7C479845C049 Q37837221-21598E21-D93E-4B45-B687-71C5C8A2A44F Q38737075-7DA81941-E05F-46D7-87E9-D7E5839F8B4E Q38748193-A24F055D-706C-4767-BCB9-24F580900D2B Q39170404-ED110C8F-B4A0-40C8-9DC9-BD8A2068D155 Q40129444-094F522C-06D0-4BFE-B4F1-34CB64BF2E3C Q40134053-CE366CB7-5AC1-46AD-9704-D501B2C0034C Q40503787-DDA09E7C-350C-438A-B71D-D0E2CDFA7756 Q40549653-8227E518-59F1-4F2A-8E2F-937F0E4A37EC Q40979359-7C8E127D-176F-49A0-8E0F-428AF0FA38E6 Q41929458-02B0B450-B3C2-47EF-B088-C818ABCC3C9E Q42366604-51206909-3A17-4600-A9A3-961E839B0864 Q42370364-E5916EA2-C93B-40F8-898D-731B89FBE4A4 Q47110306-841DBE41-7B0E-4BDE-B417-A11520D35D19 Q47134819-70AC3DFA-E392-4D3A-BA1D-FC3A53ABFEF9 Q47700986-B00B08B8-240B-4286-AB36-3040D5200A13 Q48238063-228452F5-9B69-4800-9038-BFC0373B1F2E Q50063256-8D1C1BC8-E81F-47E3-B166-E6FBB8740EE2 Q50113262-6C94B313-CB9B-49FF-B549-BF1B6EA5C92E Q50995525-2838F5FB-E879-4E18-A3E8-F8E8E1F0DC5B Q52381548-BB5CCF84-769F-4370-BF4E-906D293CA79E Q52568335-AF84C7B3-5745-41E1-8E36-EBDE67E36138 Q54626497-97772DD2-732F-4A17-8F5F-F27359F33427 Q55003489-80CE27B4-D789-48B9-82FB-D9CE287E99FB Q55454646-C667AC4B-2020-4261-AF73-323D7355ED02 Q56341814-0339FF3F-1389-4495-A0C8-534E5DE6D4B4 Q56950294-F76E30E5-E1CE-4AAC-B593-DAC22652C2A9 Q57063936-DCF18B44-3BF3-4C1B-8A73-030632DA6ACD Q57094173-FE0B2157-CA06-435A-9AFE-7711433ADCE6 Q57583616-299121F0-E372-4781-9C8E-7A9C9CD41B44 Q58556430-919B74FF-6447-4050-8AE3-BEB7C35642E5 Q58580637-E1CD903F-ED77-48DD-B974-A13D5317A1DE Q58795888-523F89E2-731E-4EE7-ACC7-12BBAC5AFB14

P2860

Recent advances of vaccine adjuvants for infectious diseases

http://www.wikidata.org/entity/Q28083679

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Recent advances of vaccine adjuvants for infectious diseases

@ast

Recent advances of vaccine adjuvants for infectious diseases

@en

Recent advances of vaccine adjuvants for infectious diseases

@nl

type

label

Recent advances of vaccine adjuvants for infectious diseases

@ast

Recent advances of vaccine adjuvants for infectious diseases

@en

Recent advances of vaccine adjuvants for infectious diseases

@nl

prefLabel

Recent advances of vaccine adjuvants for infectious diseases

@ast

Recent advances of vaccine adjuvants for infectious diseases

@en

Recent advances of vaccine adjuvants for infectious diseases

@nl

P1433

Q28083679-0CDD25F4-3562-41F2-ABA4-A4051E0EA5C1

P1476

Q28083679-D849F5F9-F5E4-4963-9610-200ADFA20872

P2093

Q28083679-1F712406-FB2B-4925-AC60-4801C1D0491D

Q28083679-AB45FB9B-BFF0-4498-8101-D4BD7FACE761

P2860

Q28083679-020B14AC-4BD3-4A25-BEFE-4E736AB70D78

Q28083679-059B0716-407D-4144-99BD-3575A09376CE

Q28083679-0B49A19A-6EAE-4FEF-97DB-98872EA7CFE8

Q28083679-10E8BACF-4517-4E43-878C-FC4EAF45C98F

Q28083679-1C605954-4653-4DE3-80F8-DE9D54F5B02A

Q28083679-244F5CC8-0D04-474A-8B06-0C139D222F34

Q28083679-376636A1-311F-499B-84E4-E7A9FA9E6ED7

Q28083679-3BBF7B4E-AB19-44ED-9DFD-A51A458F3DAE

Q28083679-3D5F10FF-7236-4B8A-947B-BEA52E3A5675

Q28083679-3EA72831-995D-4BE3-AB67-C6DB0D8B52A9

P304

Q28083679-FC3A209C-8D6B-4A72-9A72-583E53055E4E

P31

Q28083679-8983CB27-990A-4F63-8B93-E1B1C38038E3

P3181

Q28083679-78227720-3216-43DE-903B-CA005C8FD413

P356

Q28083679-6F6E4501-EBFA-46F1-AAE3-018FE887CD30

P407

Q28083679-F0C2DFBC-A8A2-41BC-AD6C-7691B45F0389

P433

Q28083679-641FEBB6-FC4C-4EDD-9367-A22669F877F1

P478

Q28083679-02C66A76-EF30-411E-B886-A0926715BA17

P577

Q28083679-261668EB-DAD5-4938-AB4F-E6DE274C1DB3

P5875

Q28083679-9ECD8EF4-412D-4D34-B775-F9A1C62D4775

P698

Q28083679-791F7131-F8AF-428C-B97C-C5F276A764A6

P932

Q28083679-85A29ECA-CC4D-4298-9D40-BE41B98230DE

P3181

P356

IN.2015.15.2.51

P1433

P1476

Recent advances of vaccine adjuvants for infectious diseases

@en

P2093

Minh Trang Nguyen

http://www.w3.org/2001/XMLSchema#string

Sujin Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections

Active and passive immunity, vaccine types, excipients and licensing

Global capacity for emerging infectious disease detection

Toll-like receptors and innate immunity

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Adjuvants for pandemic influenza vaccines.

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Formation of virosomes from influenza subunits and liposomes.

Unmet needs in modern vaccinology: adjuvants to improve the immune response.

P304

51-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1850010

http://www.w3.org/2001/XMLSchema#string

P356

10.4110/IN.2015.15.2.51

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275661453

http://www.w3.org/2001/XMLSchema#string

P698

25922593

http://www.w3.org/2001/XMLSchema#string

P932

4411509

http://www.w3.org/2001/XMLSchema#string